Karen L. McKim
This is a likely match — the affiliation was inferred from OpenAlex, ORCID, and web sources but has not been fully confirmed. Treat with appropriate caution.
Role not yet determined Is this you? Add your title
Also affiliated: United States Food and Drug Administration (1998–2021)
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Karen L. McKim's research focuses on investigating genetic mutations associated with cancer development and progression. Her work has involved the analysis of mutations in genes such as PIK3CA, KRAS, HRAS, and BRAF in various human tissues, including breast and lung, and their correlation with corresponding carcinomas. McKim has also studied temporal changes in K-ras mutant fractions in mouse lung tissue following exposure to ethylene oxide, a known carcinogen.
Her research employs molecular biology techniques, including DNA mutational analysis and targeted, error-corrected sequencing methods like CarcSeq, for the quantification of cancer driver mutations. McKim has a publication record of 28 papers with 347 citations and an h-index of 13. Her recent work in 2020 investigated erlotinib-resistant subpopulations in lung tumor organoids and the quantification of cancer driver mutations in human breast and lung DNA.
Metrics
- h-index: 13
- Publications: 27
- Citations: 343
Selected Publications
-
Assessment of Clonal Expansion Using CarcSeq Measurement of Lung Cancer Driver Mutations and Correlation With Mouse Strain- and Sex-Related Incidence of Spontaneous Lung Neoplasia (2021)
-
Quantification of cancer driver mutations in human breast and lung DNA using targeted, error‐corrected CarcSeq (2020)
-
Outgrowth of erlotinib-resistant subpopulations recapitulated in patient-derived lung tumor spheroids and organoids (2020)
-
ACB-PCR Quantification of Low-Frequency Hotspot Cancer-Driver Mutations (2020)
-
Rationale and Roadmap for Developing Panels of Hotspot Cancer Driver Gene Mutations as Biomarkers of Cancer Risk (2019)
-
Low-Frequency Mutational Heterogeneity of Invasive Ductal Carcinoma Subtypes: Information to Direct Precision Oncology (2019)
-
Lifespan Kras mutation levels in lung and liver of B6C3F1 mice (2018)
-
Variation in organ‐specific PIK3CA and KRAS mutant levels in normal human tissues correlates with mutation prevalence in corresponding carcinomas (2017)
-
Dose and temporal evaluation of ethylene oxide‐induced mutagenicity in the lungs of male big blue mice following inhalation exposure to carcinogenic concentrations (2017)
-
Ovarian effects of prenatal exposure to benzo[a]pyrene: Roles of embryonic and maternal glutathione status (2017)
-
Abstract A15: Establishing an ex-vivo, tumor spheroid culture system to assess molecular-targeted therapies for personalized treatment of non-small cell lung cancer (2016)
-
Abstract 5147: Characterization of the tissue-specific properties of cancer driver mutations suggests spontaneous mutation in normal tissues drives tumor susceptibility (2016)
-
Breast Cancer Heterogeneity Examined by High-Sensitivity Quantification of PIK3CA, KRAS, HRAS, and BRAF Mutations in Normal Breast and Ductal Carcinomas (2016)
-
Quantification of Kras mutant fraction in the lung DNA of mice exposed to aerosolized particulate vanadium pentoxide by inhalation (2015)
-
Abstract 1119: Subclonal structure of breast cancer subtypes determined by quantitative analyses of activating mutations (2015)
Collaboration Network
Top Collaborators
- Breast Cancer Heterogeneity Examined by High-Sensitivity Quantification of PIK3CA, KRAS, HRAS, and BRAF Mutations in Normal Breast and Ductal Carcinomas
- Temporal Changes in K-ras Mutant Fraction in Lung Tissue of Big Blue B6C3F1 Mice Exposed to Ethylene Oxide
- A subset of papillary thyroid carcinomas contain KRAS mutant subpopulations at levels above normal thyroid
- ACB‐PCR measurement of H‐ras codon 61 CAA→CTA mutation provides an early indication of aristolochic acid I carcinogenic effect in tumor target tissues
- Variation in organ‐specific PIK3CA and KRAS mutant levels in normal human tissues correlates with mutation prevalence in corresponding carcinomas
Showing 5 of 23 shared publications
- Breast Cancer Heterogeneity Examined by High-Sensitivity Quantification of PIK3CA, KRAS, HRAS, and BRAF Mutations in Normal Breast and Ductal Carcinomas
- Temporal Changes in K-ras Mutant Fraction in Lung Tissue of Big Blue B6C3F1 Mice Exposed to Ethylene Oxide
- A subset of papillary thyroid carcinomas contain KRAS mutant subpopulations at levels above normal thyroid
- ACB‐PCR measurement of H‐ras codon 61 CAA→CTA mutation provides an early indication of aristolochic acid I carcinogenic effect in tumor target tissues
- Variation in organ‐specific PIK3CA and KRAS mutant levels in normal human tissues correlates with mutation prevalence in corresponding carcinomas
Showing 5 of 20 shared publications
- Breast Cancer Heterogeneity Examined by High-Sensitivity Quantification of PIK3CA, KRAS, HRAS, and BRAF Mutations in Normal Breast and Ductal Carcinomas
- Outgrowth of erlotinib-resistant subpopulations recapitulated in patient-derived lung tumor spheroids and organoids
- Ovarian effects of prenatal exposure to benzo[a]pyrene: Roles of embryonic and maternal glutathione status
- Quantification of Kras mutant fraction in the lung DNA of mice exposed to aerosolized particulate vanadium pentoxide by inhalation
- Low-Frequency Mutational Heterogeneity of Invasive Ductal Carcinoma Subtypes: Information to Direct Precision Oncology
Showing 5 of 9 shared publications
- Temporal Changes in K-ras Mutant Fraction in Lung Tissue of Big Blue B6C3F1 Mice Exposed to Ethylene Oxide
- ACB‐PCR measurement of H‐ras codon 61 CAA→CTA mutation provides an early indication of aristolochic acid I carcinogenic effect in tumor target tissues
- Hotspot oncomutations: implications for personalized cancer treatment
- Abstract 1739: The prevalence of KRAS, PIK3CA, and BRAF mutant subpopulations in tumors may be impacting the success of personalized cancer treatment
- Abstract 3179: ACB-PCR quantification of PIK3CA codon 1047 CAT to CGT mutant fraction in human tumor and non-tumor tissues
- Low-Frequency Kras Mutations are Prevalent in Lung Adenocarcinomas
- Abstract 3179: ACB-PCR quantification of PIK3CA codon 1047 CAT to CGT mutant fraction in human tumor and non-tumor tissues
- Abstract B56: High sensitivity characterization of KRAS mutant subpopulations in normal lung tissue and adenocarcinomas of the lung
- Lifespan Kras mutation levels in lung and liver of B6C3F1 mice
- Abstract 1739: The prevalence of KRAS, PIK3CA, and BRAF mutant subpopulations in tumors may be impacting the success of personalized cancer treatment
- Abstract 3179: ACB-PCR quantification of PIK3CA codon 1047 CAT to CGT mutant fraction in human tumor and non-tumor tissues
- Temporal Changes in K-ras Mutant Fraction in Lung Tissue of Big Blue B6C3F1 Mice Exposed to Ethylene Oxide
- Quantification of Kras mutant fraction in the lung DNA of mice exposed to aerosolized particulate vanadium pentoxide by inhalation
- Dose and temporal evaluation of ethylene oxide‐induced mutagenicity in the lungs of male big blue mice following inhalation exposure to carcinogenic concentrations
- Temporal Changes in K-ras Mutant Fraction in Lung Tissue of Big Blue B6C3F1 Mice Exposed to Ethylene Oxide
- Quantification of Kras mutant fraction in the lung DNA of mice exposed to aerosolized particulate vanadium pentoxide by inhalation
- Dose and temporal evaluation of ethylene oxide‐induced mutagenicity in the lungs of male big blue mice following inhalation exposure to carcinogenic concentrations
- Quantification of cancer driver mutations in human breast and lung DNA using targeted, error‐corrected CarcSeq
- Rationale and Roadmap for Developing Panels of Hotspot Cancer Driver Gene Mutations as Biomarkers of Cancer Risk
- Assessment of Clonal Expansion Using CarcSeq Measurement of Lung Cancer Driver Mutations and Correlation With Mouse Strain- and Sex-Related Incidence of Spontaneous Lung Neoplasia
- Liquid Chromatographic Analysis of Incurred Amoxicillin Residues in Catfish Muscle Following Oral Administration of the Drug
- A Bridging Study Between Liquid Chromatography and Microbial Inhibition Assay Methods for Determining Amoxicillin Residues in Catfish Muscle
- Liquid Chromatographic Analysis of Incurred Amoxicillin Residues in Catfish Muscle Following Oral Administration of the Drug
- A Bridging Study Between Liquid Chromatography and Microbial Inhibition Assay Methods for Determining Amoxicillin Residues in Catfish Muscle
- Liquid Chromatographic Analysis of Incurred Amoxicillin Residues in Catfish Muscle Following Oral Administration of the Drug
- A Bridging Study Between Liquid Chromatography and Microbial Inhibition Assay Methods for Determining Amoxicillin Residues in Catfish Muscle
- Temporal Changes in K-ras Mutant Fraction in Lung Tissue of Big Blue B6C3F1 Mice Exposed to Ethylene Oxide
- Dose and temporal evaluation of ethylene oxide‐induced mutagenicity in the lungs of male big blue mice following inhalation exposure to carcinogenic concentrations
- Temporal Changes in K-ras Mutant Fraction in Lung Tissue of Big Blue B6C3F1 Mice Exposed to Ethylene Oxide
- Dose and temporal evaluation of ethylene oxide‐induced mutagenicity in the lungs of male big blue mice following inhalation exposure to carcinogenic concentrations
- Temporal Changes in K-ras Mutant Fraction in Lung Tissue of Big Blue B6C3F1 Mice Exposed to Ethylene Oxide
- Dose and temporal evaluation of ethylene oxide‐induced mutagenicity in the lungs of male big blue mice following inhalation exposure to carcinogenic concentrations
Similar Researchers
Based on overlapping research topics